BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administr...
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries BeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royaltie...
Exclusive License Focused on China and Other Key Asia-Pacific Markets Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they...